Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. Gln-1062
1. Gln-1062
2. 224169-27-1
3. Galantamine Benzoate
4. Xoi2q0zf7g
5. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Benzoate (ester), (4as,6r,8as)-
6. Benzgalantamine
7. Unii-xoi2q0zf7g
8. Benzgalantamine [inn]
9. Schembl16885442
10. [(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] Benzoate
11. Gln 1062
12. Cs-6749
13. Hy-101710
Molecular Weight | 391.5 g/mol |
---|---|
Molecular Formula | C24H25NO4 |
XLogP3 | 4.1 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 4 |
Exact Mass | 391.17835828 g/mol |
Monoisotopic Mass | 391.17835828 g/mol |
Topological Polar Surface Area | 48 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 645 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
About the Company : ors, ligands and libraries About Axon Medchem Axon Medchem is a leading European service platform for medicinal chemistry, spinned-off from Axon Biochemicals BV. Together...
About the Company : FandaChem, headquartered in Hangzhou, China, is a reputable supplier and exporter of chemicals with a focus on delivering high-quality products. Our expertise lies in exporting a w...
About the Company : Glpbio Technology Inc is a leading supplier specializing in small molecule inhibitors, activators, compound libraries, peptides, and laboratory reagents. With a vast inventory of o...
About the Company : Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical interm...
Details:
Zunveyl (benzgalantamine gluconate) is a an acetylcholinesterase inhibitor, small molecule drug being evaluated for the treatment of mild to moderate alzheimer’s disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Zunveyl
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2025
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alpha Cognition Launches ZUNVEYL for Mild to Moderate Alzheimer’s
Details : Zunveyl (benzgalantamine gluconate) is a an acetylcholinesterase inhibitor, small molecule drug being evaluated for the treatment of mild to moderate alzheimer’s disease.
Product Name : Zunveyl
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2025
Details:
Under the licensing agreement, CMS will hold the exclusive right for the development, manufacturing, and commercialization of Zunveyl (benzgalantamine) for the treatment of Alzheimer’s disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Zunveyl
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: China Medical System Holdings Limited
Deal Size: $44.0 million Upfront Cash: $6.0 million
Deal Type: Licensing Agreement January 08, 2025
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : China Medical System Holdings Limited
Deal Size : $44.0 million
Deal Type : Licensing Agreement
Alpha Cognition Signs $44M Licensing Deal for Alzheimer’s Drug ZUNVEYL
Details : Under the licensing agreement, CMS will hold the exclusive right for the development, manufacturing, and commercialization of Zunveyl (benzgalantamine) for the treatment of Alzheimer’s disease.
Product Name : Zunveyl
Product Type : Other Small Molecule
Upfront Cash : $6.0 million
January 08, 2025
Details:
The Company intends to use the proceeds towards the commercialization and launch of Zunveyl (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Zunveyl
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Titan Partners Group LLC
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 11, 2024
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Titan Partners Group LLC
Deal Size : $50.0 million
Deal Type : Public Offering
Alpha Cognition Prices $50M Upsized Public Offering and Nasdaq Listing
Details : The Company intends to use the proceeds towards the commercialization and launch of Zunveyl (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s Disease.
Product Name : Zunveyl
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 11, 2024
Details:
Zunveyl (benzgalantamine) is a new generation acetylcholinesterase inhibitor. It is being evaluated for treatment of repetitive mild traumatic brain injury.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Zunveyl
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2024
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alpha Cognition Announces Interim Data for ALPHA-1062 in Mild Traumatic Brain Injury
Details : Zunveyl (benzgalantamine) is a new generation acetylcholinesterase inhibitor. It is being evaluated for treatment of repetitive mild traumatic brain injury.
Product Name : Zunveyl
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Details:
The proceeds from the financing will be utilized to continue commercialization work for the Company’s recently approved Zunveyl (benzgalantamine), indicated for the treatment of Alzheimer's disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Zunveyl
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: The Benchmark Company
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Financing September 24, 2024
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : The Benchmark Company
Deal Size : $4.5 million
Deal Type : Financing
Alpha Cognition Completes $4.5M Convertible Note and Bridge Financing
Details : The proceeds from the financing will be utilized to continue commercialization work for the Company’s recently approved Zunveyl (benzgalantamine), indicated for the treatment of Alzheimer's disease.
Product Name : Zunveyl
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 24, 2024
Details:
ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Zunveyl
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 29, 2024
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
Details : ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine.
Product Name : Zunveyl
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2024
Details:
The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Alpha-1062
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Undisclosed
Deal Size: $6.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 22, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $6.5 million
Deal Type : Public Offering
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Product Name : Alpha-1062
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 22, 2023
Details:
The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Alpha-1062
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Undisclosed
Deal Size: $97.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 16, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $97.8 million
Deal Type : Private Placement
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
Details : The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Product Name : Alpha-1062
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 16, 2023
Details:
ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Alpha-1062
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.
Product Name : Alpha-1062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2023
Details:
The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Alpha-1062
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Undisclosed
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 31, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $1.3 million
Deal Type : Private Placement
Details : The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Product Name : Alpha-1062
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 31, 2023
Regulatory Info :
Registration Country :
Brand Name : Zunveyl
Dosage Form :
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country :
Regulatory Info :
Registration Country :
Brand Name : Zunveyl
Dosage Form :
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country :
Packaging :
Regulatory Info :
Dosage :
Dosage Strength : 5MG
Brand Name : Zunveyl
Approval Date :
Application Number :
Registration Country :
https://www.pharmacompass.com/pipeline-prospector-blog/indices-continue-to-climb-lilly-buys-morphic-for-us-3-2-bn-its-alzheimer-s-drug-finally-bags-fda-nod
18 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250319665873/en/Alpha-Cognition-Announces-the-Commercial-Launch-of-ZUNVEYL-Benzgalantamine-for-the-Treatment-of-Mild-to-Moderate-Alzheimers-Disease
12 Feb 2025
// BUSINESSWIRE
08 Jan 2025
// BUSINESSWIRE
ABOUT THIS PAGE
45
PharmaCompass offers a list of Galantamine Benzoate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Galantamine Benzoate manufacturer or Galantamine Benzoate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Galantamine Benzoate manufacturer or Galantamine Benzoate supplier.
PharmaCompass also assists you with knowing the Galantamine Benzoate API Price utilized in the formulation of products. Galantamine Benzoate API Price is not always fixed or binding as the Galantamine Benzoate Price is obtained through a variety of data sources. The Galantamine Benzoate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Galantamine Benzoate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Galantamine Benzoate, including repackagers and relabelers. The FDA regulates Galantamine Benzoate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Galantamine Benzoate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Galantamine Benzoate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Galantamine Benzoate supplier is an individual or a company that provides Galantamine Benzoate active pharmaceutical ingredient (API) or Galantamine Benzoate finished formulations upon request. The Galantamine Benzoate suppliers may include Galantamine Benzoate API manufacturers, exporters, distributors and traders.
click here to find a list of Galantamine Benzoate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Galantamine Benzoate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Galantamine Benzoate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Galantamine Benzoate GMP manufacturer or Galantamine Benzoate GMP API supplier for your needs.
A Galantamine Benzoate CoA (Certificate of Analysis) is a formal document that attests to Galantamine Benzoate's compliance with Galantamine Benzoate specifications and serves as a tool for batch-level quality control.
Galantamine Benzoate CoA mostly includes findings from lab analyses of a specific batch. For each Galantamine Benzoate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Galantamine Benzoate may be tested according to a variety of international standards, such as European Pharmacopoeia (Galantamine Benzoate EP), Galantamine Benzoate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Galantamine Benzoate USP).